VP, U.S. Medical Affairs

Company Overview

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.

At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at

The VP, U.S. Medical Affairs is the senior U.S. medical leader with end-to-end accountability for U.S. medical launch readiness, execution, and early commercialization success for Dyne’s first approved product. This role will continue to build, lead, and scale a high‑impact U.S. Medical Affairs organization and serve as a critical leader capable of delivering excellence in a first‑launch, high‑visibility environment.

This position plays a critical leadership role in shaping Dyne’s transition from a clinical‑stage to a commercial‑stage company, serving as a core member of cross‑functional launch governance and a trusted strategic advisor to executive leadership and a member of the US Leadership Team (USLT). The VP is accountable for defining and executing the U.S. medical strategy, ensuring scientific and medical excellence, mitigating medical risk, and driving impactful engagement with U.S. healthcare providers, payers, patient communities, and other external stakeholders.

The VP, U.S. Medical Affairs is a key member of the Global Medical Affairs Leadership Team and works in close collaboration with Global Medical Affairs, Commercial, Market Access, Clinical Development, Regulatory, and other functions to ensure seamless alignment and execution through approval, launch, and early lifecycle management. This is a unique opportunity to define and lead the U.S. medical strategy for Dyne’s first commercial product and establish the foundation for future launches in a rapidly evolving rare disease portfolio.

This role is based in Waltham, MA.

• Deliver a highly effective U.S. medical launch that enables appropriate, evidence‑based adoption
• Establish a credible and trusted Dyne scientific presence with U.S. KOLs, payers, and patient communities
• Build a scalable, high‑performing Medical Affairs organization ready for multiple launches
• Effectively translate scientific and clinical data into strategies that drive both access and lifecycle value
• Establish foundational capabilities and ways of working in a first‑launch environment

• Own U.S. medical strategy, launch readiness, and execution, with direct accountability for delivering multiple successful product launches from a medical affairs perspective
• Build and develop a strong leadership bench, establishing a leadership team capable of scaling with the organization and future launches
• Serve as a core member of cross‑functional launch leadership, shaping enterprise decisions and influencing cross‑functional trade‑offs, while resolving complex scientific, medical, and operational balance in a time‑critical environment
• Ensure U.S. Medical Affairs capabilities, processes, governance, and resourcing are built and operationalized to support launch and early commercialization
• Represent U.S. Medical Affairs scientific priorities and business needs at the US LT and the GMA LT
• Drive culture intentionally during scale

• Define, own, and execute the U.S. Medical Affairs strategy aligned with global medical strategy and enterprise objectives
• Ensure aligned cross‑functional strategies, goals, and execution in partnership with US LT
• Translate medical and clinical insights into actionable strategies that support appropriate product adoption, evidence generation, payer confidence, and long‑term lifecycle value
• Oversee U.S. medical tactics, including KOL strategy, advisory boards, congresses, medical education, payer engagement, and scientific exchange